M05BA07 • risedronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates
Risedronic acid is a bisphosphonate used for the prevention and treatment of osteoporosis, particularly in postmenopausal women. It is also used to treat Paget's disease of the bone.
It works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption, leading to increased bone density and reduced risk of fractures. It is taken orally, usually once a week or once a month, depending on the indication.
Common side effects include gastrointestinal disturbances such as nausea, abdominal pain, and heartburn. In rare cases, it may cause osteonecrosis of the jaw or atypical femur fractures.
Patients taking risedronic acid should follow administration instructions, such as taking the medication on an empty stomach and avoiding lying down for 30 minutes after taking it, to reduce the risk of esophageal irritation.
Substance: risedronic acid
Date of last drug list: 01-07-2015
Commercial code: W56414003
Concentration: 35mg
Pharmaceutical form: tablets
Quantity: 4
Product type: generic
Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.